Meeting News

Phase 3 data support etanercept monotherapy for PsA

December 13, 2018
CHICAGO — Phase 3 data from the SEAM-PsA study presented at the ACR/ARHP 2018 Annual Meeting showed that etanercept alone or in combination…
Meeting News

AS linked to increased risk for certain cancer types

December 12, 2018
CHICAGO — Patients with ankylosing spondylitis had an increased risk for melanoma, hematological malignancies, kidney and thyroid cancer but a…
Meeting News

COAST-W: Ixekizumab effective in hard-to-treat AS patients

November 28, 2018
CHICAGO — Ixekizumab significantly improved the signs and symptoms of ankylosing spondylitis in patients who previously did not respond to or…
Meeting News

Bimekizumab improves outcomes among PsA patients

November 27, 2018
CHICAGO — Bimekizumab, a monoclonal antibody that neutralizes both IL-17A and IL-17F, significantly improved both musculoskeletal and skin…
Meeting News

MEASURE 3: Higher secukinumab dose safe in patients with AS

November 23, 2018
CHICAGO — Phase 3 data from the MEASURE 3 trial showed that a 300-mg dose of secukinumab sustained improvements in the signs and symptoms of…
Meeting News

New referral strategy accurately detects SpA in low-prevalence setting

November 19, 2018
CHICAGO — A newly developed referral strategy for spondyloarthritis had a better balance of sensitivity and specificity than other existing…
Meeting News

Certolizumab pegol superior to placebo for non-radiographic axSpA

November 17, 2018
CHICAGO — Certolizumab pegol significantly reduced disease activity and signs of inflammation compared with placebo among patients with…
Meeting News

Statin use reduces disease activity in AS

November 16, 2018
CHICAGO — Statin use, in combination with NSAIDs, significantly reduced disease activity among patients with ankylosing spondylitis, according…
Meeting News

Chronic widespread pain affects half of axSpA patients

November 13, 2018
CHICAGO — Nearly 50% of patients with axial spondyloarthritis are affected by chronic widespread pain, with women reporting higher pain…
Meeting News

COAST-V: Ixekizumab improves AS symptoms

November 9, 2018
CHICAGO — Ixekizumab was superior to placebo in reducing disease activity while improving function, as well as spinal and sacroiliac joint…